Interaction Color Code
Clinical Bottom Line
Do not coadminister: Potential for reduced levels of dolutegravir
Drug 1
Drug 1 dose
200 mg BID
Drug 2
Drug 2 dose
50 mg daily
Drug 2 effect
Dolutegravir AUC decreased 71%; Cmin decreased 88%
Clinical Effects
Potentially reduced dolutegravir effectiveness
Management
Do not coadminister etravirine with dolutegravir unless atazanavir / ritonavir, darunavir / ritonavir, or lopinavir / ritonavir are also part of the regimen. If one of these boosted PIs is present and known or clinically suspected INSTI resistance, increase dolutegravir dosage to 50 mg BID.
Import ID
541
